Asabys Partners

Asabys Partners is a Barcelona-based venture capital firm established in 2018 that focuses on investments in the life sciences and healthcare sectors. The firm targets innovative and transformative technologies within the health-tech and biopharma industries, both in Spain and internationally. Asabys Partners aims to advance the boundaries of science and medicine by financing disruptive technologies and collaborating with leading experts in the field.

Núria Aloy

CFO

Anna Bellmunt

Associate

Eva Mendez Camarena

Venture Partner

Isabel Jiménez

Associate

Antonio Limatola

Senior Associate

Guillem Masferrer

Partner

Clara Campas

Partner and Co-Founder

Sylvain Sachot

Investment Director

Josep L.l. Sanfeliu

Managing Partner and Co-Founder

Past deals in Barcelona

Amelia Virtual Care

Series A in 2022
Psious develops a virtual reality platform designed to bring value to mental health treatment. The company's platform uses hyper-realistic virtual environments to treat anxiety disorders by means of virtual exposure therapy, enabling professionals to improve mental health therapies.

SpliceBio

Series A in 2022
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.

INBRAIN Neuroelectronics

Series A in 2021
Inbrain Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. The company focuses on developing and commercializing innovative graphene neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. By utilizing graphene technology, Inbrain creates high-density, full implantable platforms that can decode and modulate brain activity with precision. These advanced neural systems are designed to detect specific biomarkers related to therapies and to trigger targeted adaptive responses, thereby optimizing therapeutic outcomes for patients. Inbrain Neuroelectronics is dedicated to advancing the fields of neuro and bioelectronics through its cutting-edge solutions.

Koa Health

Series A in 2021
Koa Health B.V. is a company founded in 2018, headquartered in Amsterdam, with additional offices in Barcelona, the United States, and the United Kingdom. The company specializes in developing digital wellbeing and therapeutic solutions that focus on mental health support for employees. Koa Health's flagship application, koa foundation, provides organizations with tools to enhance their employees' mental well-being. The company integrates the latest clinical research with innovative technologies to offer accessible, personalized, and effective mental health resources. These resources encompass prevention, prediction, and treatment, addressing a wide range of mental health conditions.

SpliceBio

Venture Round in 2020
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.

Ona Therapeutics

Series A in 2020
Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. As a spin-off from the ICREA and Advanced Studies and the IRB Institute for Research in Biomedicine, Ona Therapeutics focuses on the discovery and development of therapeutic biologics that target tumor metastatic-initiating cells and lipid metabolism. The company's innovative therapies aim to block pathways related to fat metabolism in animal models of cancer and inhibit the cells responsible for metastasis. This approach has the potential to prevent the development of malignant tumors and eliminate existing ones, offering new treatment options for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

INBRAIN Neuroelectronics

Seed Round in 2020
Inbrain Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. The company focuses on developing and commercializing innovative graphene neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. By utilizing graphene technology, Inbrain creates high-density, full implantable platforms that can decode and modulate brain activity with precision. These advanced neural systems are designed to detect specific biomarkers related to therapies and to trigger targeted adaptive responses, thereby optimizing therapeutic outcomes for patients. Inbrain Neuroelectronics is dedicated to advancing the fields of neuro and bioelectronics through its cutting-edge solutions.

Anaconda Biomed

Series B in 2019
Anaconda Biomed, founded in 2015 and based in Barcelona, Spain, is an innovative medical technology company focused on developing advanced healthcare devices for the treatment of acute ischemic stroke (AIS). The company specializes in neuro-thrombectomy systems, notably the ANCD BRAIN™, a third-generation stented aspiration thrombectomy system. This system is designed to perform mechanical thrombectomies using a combination of a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. When deployed, the stent retriever expands to conform to the artery, effectively halting blood flow and enabling the complete extraction of thrombus without fragmentation. This technology aims to provide immediate treatment for stroke patients, significantly reducing the risk of fatality.

Ona Therapeutics

Seed Round in 2019
Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. As a spin-off from the ICREA and Advanced Studies and the IRB Institute for Research in Biomedicine, Ona Therapeutics focuses on the discovery and development of therapeutic biologics that target tumor metastatic-initiating cells and lipid metabolism. The company's innovative therapies aim to block pathways related to fat metabolism in animal models of cancer and inhibit the cells responsible for metastasis. This approach has the potential to prevent the development of malignant tumors and eliminate existing ones, offering new treatment options for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

Amelia Virtual Care

Venture Round in 2019
Psious develops a virtual reality platform designed to bring value to mental health treatment. The company's platform uses hyper-realistic virtual environments to treat anxiety disorders by means of virtual exposure therapy, enabling professionals to improve mental health therapies.

Amelia Virtual Care

Series A in 2019
Psious develops a virtual reality platform designed to bring value to mental health treatment. The company's platform uses hyper-realistic virtual environments to treat anxiety disorders by means of virtual exposure therapy, enabling professionals to improve mental health therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.